Sponsor
Charles Drew University of Medicine and Science
Clinical research sponsor
Clinical trials
32 shownGreen Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer PatientsNCT06615752 · lead sponsor · 2026-10-01
RECRUITINGTrauma Informed Childhood Obesity Care for Low-Income Minorities in Primary CareNCT04980001 · lead sponsor · 2024-06-01
WITHDRAWNA Mental Health Intervention for a Community Program Called the PowerObesityNCT05605028 · lead sponsor · 2023-09-02
WITHDRAWNImpact of Colorectal Cancer and Nutrition Education Program Among Minority Patients With Type 2 DiabetesNCT05765214 · lead sponsor · 2023-05-01
ACTIVE_NOT_RECRUITINGEntre Herman@s: Promoting Health Among Latino MSMNCT05805306 · lead sponsor · 2023-04-29
COMPLETEDAdvancing DSME/S and COVID-19 Prevention and Protection Through "emPOWERed to Change" ProgramNCT04993326 · lead sponsor · 2022-01-10
WITHDRAWNImproving Survivorship Among Minority Cancer DyadsNCT04685551 · lead sponsor · 2021-07-01
WITHDRAWNObesity Group Visits. A Novel Way to Approach the Obesity Epidemic in an Inner-City SettingNCT04725058 · lead sponsor · 2020-02-03
ACTIVE_NOT_RECRUITINGPredicting Diabetic Retinopathy From Risk Factor Data and Digital Retinal ImagesNCT03694145 · lead sponsor · 2018-10-25
ACTIVE_NOT_RECRUITINGEfficacy of Mifepristone in Males With Type 2 Diabetes MellitusNCT03052400 · lead sponsor · 2017-02-03
TERMINATEDReducing HIV Risk With High Risk HIV Negative Black MSM-Passport to WellnessNCT02932384 · lead sponsor · 2015-08-01
COMPLETEDHydroxychloroquine Versus Pioglitazone in Combination Treatment for Type 2 Diabetes MellitusNCT02303405 · lead sponsor · 2014-11-01
TERMINATEDFemales of African American Legacy Empowering Self (FemAALES)NCT02189876 · lead sponsor · 2013-07-01
COMPLETEDImpact of Exergaming on Adolescent YouthNCT01374386 · lead sponsor · 2010-10-01
WITHDRAWNVitamin D in Minorities With PrediabetesNCT00876928 · lead sponsor · 2009-03-01
COMPLETEDDance Dance Revolution (DDR) in Type 2 DiabetesNCT00851019 · lead sponsor · 2009-02-01
COMPLETEDSitagliptin in Combination With Metformin and SulfonylureaNCT00686634 · lead sponsor · 2008-01-01
COMPLETEDMen of African American Legacy Empowering SelfNCT01492530 · lead sponsor · 2007-08-01
COMPLETEDTreatment of Diabetes and Depression in Hispanics and African Americans and Its Effect on A1c and Quality of Life.NCT00624013 · lead sponsor · 2006-09-01
COMPLETEDLow Dose Versus Aggressive Inhibition of the Renin-Angiotensin-Aldosterone (RAS) to Treat MicroalbuminuriaNCT00907374 · lead sponsor · 2005-07-01
COMPLETEDExercise Dose-Response on Features of the Metabolic SyndromeNCT00687128 · lead sponsor · 2004-10-01
COMPLETEDInsulin Glargine Versus Twice-Daily NPHNCT00687453 · lead sponsor · 2003-02-01
TERMINATEDInsulin Glargine at Bedtime or in AM Versus NPHNCT00686712 · lead sponsor · 2003-02-01
COMPLETEDPhase II Randomized Study of Physiologic Testosterone Replacement in Premenopausal, HIV-Positive WomenNCT00004400 · lead sponsor · 1997-04-01
COMPLETEDCalifornia MEPS HubNCT07433985 · collaborator · 2025-12-01
RECRUITINGThe INSPIRE -Faith Study: Intervention Strategies for Preserving Intellectual Resilience and EngagementNCT06741865 · collaborator · 2025-06-01
RECRUITINGMobile Enhanced Prevention Support for People Leaving JailNCT04036396 · collaborator · 2019-11-14
COMPLETEDGarden-fresh Produce and Exercise Reduce Colon Cancer RiskNCT03976284 · collaborator · 2019-03-17
UNKNOWNBiobran/MGN-3 Increases Innate Resistance and Reduces the Incidence of Influenza-like IllnessesNCT04646980 · collaborator · 2018-11-28
COMPLETEDThe HJ MILE HIV Prevention Intervention for Post-incarcerated MenNCT01427543 · collaborator · 2011-07-01
COMPLETEDTestosterone and Physical Function in HIV+ MenNCT00260143 · collaborator · 2003-05-01
COMPLETEDStress Reduction in the Prevention of Left Ventricular HypertrophyNCT05373732 · collaborator · 1996-04-01
COMPLETEDSponsor roles
lead sponsor24
collaborator8
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.